CD38 and Miyoshi myopathy: Daratumumab (sold under the brand name “Darzalex”), a fully humanized IgG1-κ MoAb directed against two β-strands (amino acids 233–246 and 267–280) of CD38, induces potent ADCC and CDC in MM cell lines and primary MM cells [10] and directly induces apoptosis through Fc receptor-mediated crosslinking [11] and caspase activation [12].